一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Drugs >>article
Drugs

Drugs

IF: 13
Download PDF

Letermovir: First Global Approval.

Published:1 January 2018 DOI: 10.1007/s40265-017-0860-8 PMID: 29288370
Esther S Kim

Abstract

Letermovir (Prevymis?) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT). In addition, letermovir has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, and is under review in several countries, including Japan. This article summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Letermovir 917389-32-3 C29H28F4N4O4 271 suppliers $15.00-$4741.00
Letermovir 710312-77-9 C34H47N11O9S2 8 suppliers Inquiry

Similar articles

IF:4.1

Capmatinib: First Approval.

ACS Chemical Neuroscience Sohita Dhillon,etc Published: 1 July 2020
IF:3.4

Sodium Thiosulfate: Pediatric First Approval.

Pediatric Drugs Sohita Dhillon,etc Published: 1 March 2023
IF:3.4

Letermovir for cytomegalovirus prophylaxis

Australian Prescriber Published: 24 April 2019
湟源县| 罗平县| 仪征市| 西和县| 马山县| 腾冲县| 乐平市| 留坝县| 蛟河市| 巴楚县| 拜城县| 吉木乃县| 河池市| 汤阴县| 大安市| 皮山县| 建始县| 治县。| 京山县| 常山县| 阿克陶县| 吉林市| 三台县| 玛多县| 武夷山市| 清流县| 嘉禾县| 漳浦县| 廊坊市| 马边| 虞城县| 五峰| 义乌市| 湘潭市| 峨眉山市| 大方县| 衡东县| 泾阳县| 安溪县| 贵州省| 中西区|